Authorizes Cofpres vaccine against influenza types A and B

angeles cruz martinez

Newspaper La Jornada
Friday 4 August 2023, p. 3.4

The Federal Commission for the Protection of Sanitary Risks (COFEPRIS) reported yesterday on the authorization of 159 sanitary registries, of which 14 are for medicines and the rest for equipment. It also approved the conduct of seven clinical trials.

In a statement, he highlighted the approval for sale in Mexico of the tetravalent influenza vaccine from the Sanofi laboratory. The biologic has protection against subtypes A and B with doses higher than those known to be applicable nationally, as it is aimed at adults over the age of 65.

In this regard, the French capital company indicated that this organic is manufactured in the United States and, for now, in Mexico it will be available only in the private sector.

The new biologic contains four times more antigen than conventional vaccines. This is because the body’s defense system weakens with age and higher doses increase protection against the influenza virus.

Sanofi said the vaccine has been used in other countries for 10 years, and although it already has a health registration in Mexico, it will not yet be available for the next winter season.

Meanwhile, Cofepris also authorized an antiplatelet agent for the treatment of cardiovascular diseases.

In the report on authorizations released in the second half of July, Coffeprice indicated that 54 of the 145 devices are for medical care; are, among others, an ultrasound intravascular catheter, intervertebral fixation device and stent Intracranial self-expanding stent.

There are also 52 teams dedicated to lipids, liver function, hormones, rheumatology and diagnosis of infectious diseases, and 39 medical equipment such as oxygen concentrators, fetal dopplers, surgical instruments, X-ray and ultrasound systems.

Regarding clinical trials, it was indicated that two are for the treatment of systemic lupus erythematosus and one for chronic kidney transplant rejection.


Source link

Leave a Comment